Evidence map›Paper›PMID 41868263›Full record

ArticleJournal of hepatocellular carcinoma2026

Nomogram Using Taurocholic Acid, Age, and Albumin to Predict HBV-Related Cirrhosis/HCC in CHB Patients.

Xuemei Zhang, Liming Zheng, Wenlan Zheng, Jia Shi, Shihan Yu, Hao Liu, Hai Feng, Zhuo Yu

Abstract read
In one paragraph

Article in Journal of hepatocellular carcinoma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xuemei Zhang *Department of Hepatopathy, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, People's Republic of China.
Liming Zheng *Department of Hepatopathy, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, People's Republic of China.
Wenlan ZhengDepartment of Hepatopathy, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, People's Republic of China.
Jia ShiDepartment of Hepatopathy, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, People's Republic of China.
Shihan YuDepartment of Hepatopathy, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, People's Republic of China.
Hao LiuDepartment of Hepatopathy, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, People's Republic of China.
Hai Feng *Department of Hepatopathy, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, People's Republic of China.ORCID 0000-0001-9820-7111
Zhuo Yu *Department of Hepatopathy, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, People's Republic of China.ORCID 0000-0003-4100-8415

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Progression to liver cirrhosis (LC) and hepatocellular carcinoma (HCC) is a severe epidemiological risk factor for chronic hepatitis B (CHB); therefore, effective monitoring strategies are urgently required. Dysregulation of bile acids (BAs) metabolism is crucial for aggravating the pathological processes of liver diseases. In this study, we aimed to develop a risk model based on the BAs signature to predict the likelihood of LC and HCC occurrence in CHB patients. Patients and Methods: A retrospective analysis was conducted using the clinical data of 609 patients diagnosed with CHB, HBV-related LC, and HCC. Patients were randomly assigned to a training or validation set. Logistic regression analyses were employed in the training set to identify key variables and establish a nomogram risk model for predicting the progression of CHB to LC and HCC. Accuracy, calibration, and clinical utility of the model were assessed using a validation set. Results: Taurocholic acid level and age were independent risk factors, and serum albumin level was a protective factor against the progression of CHB to LC and HCC. A Nomogram risk model was developed using these three indicators, demonstrating a highly accurate and reliable ability to predict the progression from CHB to LC and HCC with good clinical validity and utility. Conclusion: This study developed a nomogram incorporating BA markers, enabling precise prediction of LC and HCC in patients with CHB. This provided an accurate and accessible method for early screening and prevention.

Indexed as

bile acidschronic hepatitis BHCCliver cirrhosisnomogram

Identifiers

PMID41868263
PMCPMC13005188

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.